Khosla Ventures Targets Nearly $4 Billion in New Funds

Khosla Ventures Targets Nearly $4 billion in New Funds

Khosla Ventures sets sights on $4 billion in new funds

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, friends! We’re back. Hope you are having a delightful summer (or winter, I suppose, depending on your hemisphere). Today, we talk about morale at the FDA and potential fallout, see how the agency’s posture toward China could affect biotechs, and more. The need-to-know this morning The FDA approved a pill from KalVis…

KalVista bags FDA approval for delayed oral HAE drug

KalVista has brought the first oral, on-demand treatment for hereditary angioedema attacks to the US market

KalVista Shares Surge as FDA Approves New Drug After Delay

KalVista Pharmaceuticals Inc. shares rose 19% early Monday after the company said it received US Food and Drug Administration approval for its pill for hereditary angioedema, a rare and potentially deadly condition that causes severe swelling throughout the body.

KalVista’s Ekterly for Hereditary Angioedema Attacks Approved by FDA

The U.S. Food and Drug Administration, Public domain, via Wikimedia Commons KalVista Pharmaceuticals’ Ekterly (sebetralstat) has been approved by the U.S. FDA to treat attacks of hereditary angioedema (HAE), a rare disease that causes serious swelling in different parts of the body such as the face and limbs. “As the first orally administered on-demand therapy for HAE attacks, Ekterly provides patients and physicians with an important and welcom…

KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) rose sharply during Monday's session after the company announced it won FDA approval for EKTERLY. The U.S. Food and Drug Administration (FDA) on Monday…